AIM Targeted Therapies has two products that provide revolutionary methods of modulating the physiological pathways of the body to produce predictable outcomes for pain relief; and infection control with healing properties. We offer BDA12 and ZAPP that address unmet needs of the opioid crises and topical antimicrobial resistance. We will present our work encompassing more than two decades of human and animal research. These candidate products will benefit patients in the areas of pain control (BDA12) and antimicrobial action (ZAPP) against bacteria, viruses and fungi, healing with full tissue regeneration and minimal scarring. Both products have patents accepted and/or pending globally.